VSTM icon

Verastem

5.73 USD
+0.00
0.00%
At close Jan 10, 4:00 PM EST
After hours
5.76
+0.03
0.52%
1 day
0.00%
5 days
-19.75%
1 month
14.60%
3 months
92.28%
6 months
109.89%
Year to date
-11.71%
1 year
-45.06%
5 years
-72.87%
10 years
-94.89%
 

About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Employees: 73

0
Funds holding %
of 6,810 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

338% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 8

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

76% more capital invested

Capital invested by funds: $45.2M [Q2] → $79.5M (+$34.3M) [Q3]

12% more funds holding

Funds holding: 67 [Q2] → 75 (+8) [Q3]

6.3% more ownership

Funds ownership: 59.82% [Q2] → 66.12% (+6.3%) [Q3]

6% less call options, than puts

Call options by funds: $137K | Put options by funds: $145K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
22%
upside
Avg. target
$10.67
86%
upside
High target
$16
179%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Gregory Renza
45% 1-year accuracy
38 / 84 met price target
179%upside
$16
Outperform
Maintained
7 Jan 2025
Mizuho
Mara Goldstein
50% 1-year accuracy
2 / 4 met price target
57%upside
$9
Outperform
Maintained
19 Dec 2024
HC Wainwright & Co.
Sean Lee
67% 1-year accuracy
14 / 21 met price target
22%upside
$7
Buy
Reiterated
19 Dec 2024

Financial journalist opinion

Based on 7 articles about VSTM published over the past 30 days

Neutral
Business Wire
3 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
1 week ago
Verastem: Planning The PDUFA Run-Up
Verastem, Inc.'s NDA for avutometinib and defactinib in recurrent KRAS-mutant LGSOC has been accepted by the FDA, with a PDUFA date set for June 30, 2025. The combination therapy shows promising Phase II RAMP 201 results, with a 31% ORR and significant tumor size reduction, potentially positioning Verastem as a commercial-stage company by 2025. The LGSOC market is projected to reach $363.7M by 2034, with Verastem's therapy poised to capture a significant share due to the lack of approved treatments.
Verastem: Planning The PDUFA Run-Up
Positive
Seeking Alpha
1 week ago
Verastem: BLA Acceptance Puts Key Goals In Sight
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves, with only 4-5 quarters of operating funds, posing a risk if there are approval delays. The market size for their therapy is uncertain, with potential revenues ranging from $85.7 million to $686 million annually.
Verastem: BLA Acceptance Puts Key Goals In Sight
Positive
Zacks Investment Research
1 week ago
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
Positive
Benzinga
1 week ago
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?
On Monday, the FDA accepted for review the New Drug Application under the accelerated approval pathway for Verastem Oncology's VSTM avutometinib.
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?
Neutral
Business Wire
1 week ago
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC), wh.
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Neutral
Business Wire
3 weeks ago
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). No dose-limiting toxicities (DLTs) have been observed in the triplet combination. RAMP 203 continues to progress, with additional enroll.
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Positive
Seeking Alpha
1 month ago
Verastem: Preparing For Upcoming Catalysts
Verastem's avutometinib and defactinib show promising clinical progress for recurrent KRAS-mutant LGSOC, with potential FDA approval and market launch by mid-2025. The company's strong cash position and strategic focus on RAS-driven cancers offer significant growth opportunities without imminent dilution risks. Upcoming catalysts include FDA filing decisions, interim data from NSCLC and pancreatic cancer trials, and potential commercial launch, driving Verastem's bullish outlook.
Verastem: Preparing For Upcoming Catalysts
Neutral
Business Wire
1 month ago
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.verastem.com. A repla.
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Neutral
Business Wire
2 months ago
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the third quarter ended September 30, 2024. “In the third quarter of 2024, we made advancements in our recurrent low-grade serous ovarian cancer program, including sharing updated Phase 2 RAMP 201 data demonstrating robust and durable response rates, tumor reductions across a majo.
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Charts implemented using Lightweight Charts™